Brought to you by 
Lilly pays $110mm up front plus earn-outs to acquire AurKa Pharma and regain cancer candidate
03 Sep 2020
Executive Summary
Eli Lilly & Co. penned its second oncology acquisition in one week, agreeing to acquire privately held AurKa Pharma Inc. for $110mm up front, plus up to $465mm in regulatory- and sales-based earn-outs.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lilly pays $110mm up front plus earn-outs to acquire AurKa Pharma and regain cancer candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice